My sister called me at 11pm on a Tuesday in tears. She’d spent three hours on TikTok watching semaglutide content, then another hour reading her doctor’s visit notes, and she had no idea which reality was true.
TikTok said: semaglutide is a miracle. You’ll lose 20 pounds in two months. Just inject it once a week. Her doctor’s notes said: “discussed Ozempic; patient not an appropriate candidate due to cost concerns; advised lifestyle modification.” Those two things were irreconcilable, and she needed someone to explain the gap.
I’m a biochemist. I spent five years in graduate school studying receptor pharmacology. I know exactly what happens at the molecular level when semaglutide binds to a GLP-1 receptor, and I also know that none of that shows up in TikTok videos or in a four-minute appointment with a busy primary care doctor.
So I spent that entire Wednesday writing my sister a document. I pulled the STEP 1 trial data. I explained why the average 15% weight loss over 68 weeks doesn’t mean 20 pounds in two months. I walked through the GI side effect profile and why the slow titration protocol exists. I explained that “not an appropriate candidate due to cost” is actually “your insurance won’t cover it and your doctor doesn’t know about the telehealth options,” which is a solvable problem, not a medical verdict.
She forwarded it to six friends before the week was out.
This site is the longer version of that document.
What I actually do
My background is molecular biology and receptor pharmacology. I did my PhD on GPCR signaling — which is the protein family that GLP-1 receptors belong to — so semaglutide’s mechanism is something I understand at a level that most health writers don’t. That’s not a flex; it’s just the reason this site exists rather than me leaving it to someone else.
The thing that frustrates me about most semaglutide content — even the ostensibly good stuff — is that it treats women as a footnote. The clinical trials stratify by sex because they have to. The data is right there. Women lose more weight on average, report more GI side effects, and benefit from slower titration. PCOS and perimenopausal status both affect response in documented ways. None of this is secret or controversial — it’s published in the same journals everyone’s citing.
But the summary articles and the dosing guides and the Reddit megathreads were written about a composite patient who doesn’t have a menstrual cycle or PCOS or the hormonal complexity that shapes how women’s metabolism actually works. So either you have a biochemistry PhD and can read the papers yourself, or you’ve been getting advice calibrated for someone else’s body.
I write about semaglutide the way I explained it to my sister: here’s what’s actually happening at the molecular level, here’s what that means practically, here’s where the evidence is strong and where it gets complicated.
The TikTok vs. doctor problem
My sister’s problem wasn’t that she’d been lied to by TikTok or neglected by her doctor. Her problem was that she was getting two kinds of information that don’t speak to each other.
TikTok GLP-1 content is almost entirely anecdote. It’s real people with real results, but it’s not calibrated — you’re seeing the people who had great outcomes and wanted to talk about it. The 15% trial average includes the people who lost 5% and the people who lost 28%. TikTok shows you a lot of the 28% and almost none of the 5%.
Primary care doctors, meanwhile, are working with maybe 90 seconds of training on GLP-1 pharmacology and a formulary that usually doesn’t cover semaglutide unless you have Type 2 diabetes. Most of them aren’t trying to dismiss you. They don’t have time to explain the telehealth pathway and they haven’t been told to look for it.
The gap between those two things is where most women get stuck. The research is good. The access pathway exists. But synthesizing it into something useful takes either a PhD or someone willing to do the work.
I’m willing to do the work.
On telehealth and the affiliate disclaimer
This site has an affiliate relationship with Delilah, a telehealth platform that connects women with licensed GLP-1 prescribers. When you sign up through my link, I earn a referral fee. I want to be upfront about that.
The reason I write about telehealth at all: it’s the practical solution to the access problem. Brand-name semaglutide costs $800 to $1,200 a month out of pocket. Telehealth platforms like Delilah connect you with licensed prescribers who can evaluate whether GLP-1 therapy makes sense for your specific situation. This is not a workaround or a shortcut — it’s a licensed medical pathway that exists and works and most women don’t know about.
The affiliate relationship doesn’t change which services I recommend or why. It means I only write about the ones I’d tell my sister to use, because those are the only ones worth the space on this site. I looked at several of these services before deciding to recommend Delilah specifically. They require real medical intake, assign licensed prescribers, and have declined patients who were not appropriate candidates. That last part matters.
See the full affiliate disclosure if you want the details.
Where to start
If you’re trying to understand semaglutide and you have PCOS, start with the PCOS piece — the mechanism is particularly relevant there and the benefit extends beyond just weight loss.
If you’re in perimenopause or menopause, the menopause article covers why the hormonal context changes the response profile and what the emerging research on combining GLP-1 therapy with HRT actually shows.
If you want the practical path, Delilah is where I would start. The vendor overview is the place to start.
And if you want to understand the molecular basics before diving into any of it, the article on what the clinical research actually shows for women is a good foundation.
Photo: [placeholder for author headshot]
Olivia Nightingale is a biochemist and science writer based in Denver. Her background is in molecular biology and receptor pharmacology, with a focus on GPCR signaling. She writes about GLP-1 research for women who want the actual science, not the TikTok version.